Ab­b­Vie clos­es in on Bio­haven with new mi­graine pre­ven­tion OK for oral CGRP drug

4 years ago
Pharma
FDA+

FDA calls for re­peat bioe­quiv­a­lence stud­ies af­ter un­cov­er­ing 'in­valid' da­ta from two In­di­an CROs

4 years ago
Outsourcing
FDA+

Drug­ging RNA was once con­sid­ered im­pos­si­ble. Now Big Phar­ma can't get enough of it

4 years ago
Financing

I-Mab in talks about deals, stake sale to build on $3B Ab­b­Vie al­liance — Bloomberg

4 years ago
Deals
China

As­traZeneca wa­gers on $500M buy­out, plucks PhI­II drug for Alex­ion’s rare dis­ease pipeline — and jumps straight ...

4 years ago
Deals

As sup­ply chain wor­ries ease up, Big Phar­ma CEOs have a new top con­cern: re­cruit­ing and keep­ing em­ploy­ees

4 years ago
People
Pharma

NIH spot­lights trio of aca­d­e­m­ic teams chas­ing af­ter 'pan-coro­n­avirus' vac­cines

4 years ago
Discovery

Con­tract re­search is hav­ing a mo­ment right now. Will M&A splash­es dri­ve the in­dus­try to even greater heights?

4 years ago
Outsourcing
In Focus

Safe­ty fears force Pfiz­er to change piv­otal DMD gene ther­a­py tri­al pro­to­col

4 years ago
R&D
Cell/Gene Tx

French biotech and Pfiz­er find pos­i­tives in da­ta for Ly­me dis­ease vac­cine can­di­date; Al­tim­mune's obe­si­ty drug shows ...

4 years ago
News Briefing

Zio­pharm lays off half its staff af­ter man­u­fac­tur­ing is­sues force de­lays

4 years ago
People
Pharma

Covid-19 roundup: Pfiz­er/BioN­Tech sub­mit vac­cine da­ta to FDA for younger chil­dren; Doc­tors kept pre­scrib­ing ...

4 years ago
Coronavirus

George Church, his stu­dents, and top VCs go na­tion­wide with a biotech train­ing camp

4 years ago
Startups

Bank­ing on in­te­grase in­hibitors as HIV cor­ner­stone, Vi­iV bags 3rd-gen­er­a­tion com­pound from Sh­iono­gi

4 years ago
Deals

On a jour­ney to dras­ti­cal­ly speed up cell ther­a­py man­u­fac­tur­ing, Ky­topen lands $30M Se­ries A

4 years ago
Financing
Startups

Sanofi calls it quits on mR­NA Covid-19 shots, scrap­ping vac­cine from $3.2B Trans­late Bio buy­out

4 years ago
R&D
Coronavirus

Tur­moil at CBER: Pe­ter Marks grabs con­trol of FDA's Of­fice of Vac­cines ahead of 2 key ca­reer leader de­par­tures

4 years ago
FDA+
Coronavirus

Look­ing to rewrite the rules of drug li­cens­ing, start­up An­ji is on the hunt for 'dy­nam­ic eq­ui­ty' joint ven­tures

4 years ago
Financing
R&D

In­novent bets $250M+ on Union's PDE4 in­hibitor ahead of a PhII read­out

4 years ago
Deals
China

Seiz­ing Aduhelm prece­dent, Bio­gen, Ei­sai get the ball rolling on an­oth­er ac­cel­er­at­ed Alzheimer's ap­proval

4 years ago
FDA+

Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

4 years ago
Deals
Pharma

Opin­ion: How the con­fus­ing boost­er shot de­ba­cle aligns Biden with Trump's pan­dem­ic re­sponse

4 years ago
Coronavirus
Opinion

Evelo touts PhII win for in­flam­ma­tion pro­gram; In­novent, An­Heart claim in­ter­im PhII suc­cess in NSCLC

4 years ago
News Briefing

Af­ter pump­ing the brakes on their An­gel­man syn­drome study, Ul­tragenyx and GeneTx are back in the race

4 years ago
FDA+
First page Previous page 634635636637638639640 Next page Last page
A service from the Financial Times